IR-Med Dividend Coverage

What does IR-Med do? IR-Med, Inc. develops non-invasive medical devices using Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company focuses on two principal products: PressureSafe, a handheld optical monitoring device for early detection of pressure injuries, and Nobiotics, an otoscope providing immediate indications for medical conditions. Healthcare professionals purchase these devices to detect biomarkers and molecules in real-time without invasive procedures. The company's initial product candidates are in various development stages, targeting medical indications requiring non-invasive diagnostics. IR-Med, Inc. generates revenue through the sale of PressureSafe and Nobiotics to healthcare providers. The devices are designed for specific medical applications, with PressureSafe addressing pressure injuries in bedridden patients and Nobiotics supporting physicians in otoscopic examinations. The company's business model centers on developing and commercializing these AI-enhanced medical devices to meet unmet diagnostic needs in healthcare settings. The firm's products are developed for real-time detection of biomarkers in blood and tissue, eliminating the need for invasive procedures. PressureSafe targets healthcare professionals managing bedridden patients, while Nobiotics serves physicians requiring immediate diagnostic insights during examinations. IR-Med, Inc. monetizes its technology through direct sales of these specialized medical devices to healthcare institutions and practitioners. IR-Med is one of the most popular companies on Eulerpool.